Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479607 | 1.00 | BACE1 (0.48) | BACE1SMN1; SMN2SIGMAR1ALDH1A1POLB | |
| SCHEMBL2818279 | 1.00 | BACE1 (0.48) | BACE1SMN1; SMN2SIGMAR1ALDH1A1POLB | |
| SCHEMBL2818282 | 1.00 | BACE1 (0.48) | BACE1SMN1; SMN2SIGMAR1ALDH1A1POLB | |
| SCHEMBL6045741 | 0.89 | SMN1; SMN2 (0.55) | BACE1SMN1; SMN2SIGMAR1 | |
| SCHEMBL2432803 | 0.86 | BACE1 (0.55) | BACE1KMT2A | |
| SCHEMBL8177737 | 0.83 | BACE1 (0.42) | BACE1SMN1; SMN2SIGMAR1KMT2A | |
| SCHEMBL3492690 | 0.82 | KDM4E (0.36) | BACE1SMN1; SMN2 | |
| SCHEMBL3492694 | 0.82 | KDM4E (0.36) | BACE1SMN1; SMN2 | |
| SCHEMBL3492688 | 0.82 | KDM4E (0.36) | BACE1SMN1; SMN2 | |
| SCHEMBL8203758 | 0.82 | KDM4E (0.36) | BACE1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117309-B1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8377954-B2 | Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Corp (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | BACE1 1/4885SMN1; SMN2 2111/4885SIGMAR1 4304/4885 |
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | BACE1 1/4885SMN1; SMN2 2196/4885SIGMAR1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.